This was the first commercial enterprise with which TDB signed an agreement for providing loan assistance to develop and commercialise a product- Hepatitis-B vaccine on 9th April, 1997. ‘Hepatitis-B’ is a viral infection of the liver and a major health problem in India. The company launched India’s first genetically engineered human health care product ‘Shanvac-B’ in August 1997. The product is import substitute and cost effective.
The company has indigenously developed the technology for tetravalent vaccine ‘DPT and Hepatitis-B’ and has successfully started the commercial production of the vaccine.
The company was the first recipient of the National Award by TDB in the year 2000.